Next Article in Journal
Erratum: Huet, R.; et al. 1,1-Difluoroethane Detection Time in Blood after Inhalation Abuse Estimated by Monte Carlo PBPK Modeling. Pharmaceutics, 2020, 12, 997
Previous Article in Journal
The Biosimilar Landscape: An Overview of Regulatory Approvals by the EMA and FDA
Review

Targeted Alpha Therapy: Progress in Radionuclide Production, Radiochemistry, and Applications

1
Department of Oncology, University of Alberta, 11560 University Ave, Edmonton, AB T6G 1Z2, Canada
2
Edmonton Radiopharmaceutical Center, Alberta Health Services, 11560 University Ave, Edmonton, AB T6G 1Z2, Canada
*
Author to whom correspondence should be addressed.
Pharmaceutics 2021, 13(1), 49; https://doi.org/10.3390/pharmaceutics13010049
Received: 2 December 2020 / Revised: 15 December 2020 / Accepted: 23 December 2020 / Published: 31 December 2020
(This article belongs to the Section Biopharmaceutics)
This review outlines the accomplishments and potential developments of targeted alpha (α) particle therapy (TAT). It discusses the therapeutic advantages of the short and highly ionizing path of α-particle emissions; the ability of TAT to complement and provide superior efficacy over existing forms of radiotherapy; the physical decay properties and radiochemistry of common α-emitters, including 225Ac, 213Bi, 224Ra, 212Pb, 227Th, 223Ra, 211At, and 149Tb; the production techniques and proper handling of α-emitters in a radiopharmacy; recent preclinical developments; ongoing and completed clinical trials; and an outlook on the future of TAT. View Full-Text
Keywords: targeted alpha therapy; alpha particle therapy; targeted radionuclide therapy; theranostics; actinium-225; bismuth-213; astatine-211; radium-223; thorium-227; terbium-149 targeted alpha therapy; alpha particle therapy; targeted radionuclide therapy; theranostics; actinium-225; bismuth-213; astatine-211; radium-223; thorium-227; terbium-149
Show Figures

Figure 1

MDPI and ACS Style

Nelson, B.J.B.; Andersson, J.D.; Wuest, F. Targeted Alpha Therapy: Progress in Radionuclide Production, Radiochemistry, and Applications. Pharmaceutics 2021, 13, 49. https://doi.org/10.3390/pharmaceutics13010049

AMA Style

Nelson BJB, Andersson JD, Wuest F. Targeted Alpha Therapy: Progress in Radionuclide Production, Radiochemistry, and Applications. Pharmaceutics. 2021; 13(1):49. https://doi.org/10.3390/pharmaceutics13010049

Chicago/Turabian Style

Nelson, Bryce J.B., Jan D. Andersson, and Frank Wuest. 2021. "Targeted Alpha Therapy: Progress in Radionuclide Production, Radiochemistry, and Applications" Pharmaceutics 13, no. 1: 49. https://doi.org/10.3390/pharmaceutics13010049

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop